Program
org-34517
Also written as “PT150” and “SCH 900636”.
Its studies are mostly in Alcoholism · Depressive Disorder, led by 2 companies.
Furthest: phase 2, since May 10, 20184 company-led studies, 1 open or runningNext primary completion: Jul 31, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pop Test Oncology | 31 open or running | phase 1since May 10, 2018 | May 10, 2018 | Jul 31, 2028phase 1 · NCT06712602 |
| Merck | 10 open or running | phase 2since Feb 11, 2009 | Feb 11, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 11, 2009First study: phase 2 study in Depressive DisorderNew to MerckMerck · NCT00844922 · 16 enrolled
- May 10, 2018Pop Test Oncology's first study: phase 1 study in AlcoholismNew to Pop Test OncologyPop Test Oncology · NCT03548714 · 10 enrolled · United States
- Mar 31, 2020Phase 1 study in AlcoholismPop Test Oncology · NCT04331288 · 10 enrolled · United States
- Nov 26, 2024Phase 1 study in AlcoholismPop Test Oncology · NCT06712602 · 34 planned · United States
Ahead
- Jul 31, 2028Primary completion: phase 1 study in AlcoholismPop Test Oncology · NCT06712602
TargetBeta
NR3C1 →read by rule
“Glucocorticoid receptor antagonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06712602Alcoholism · United States | 1 | Recruiting | Pop Test Oncology | Jul 31, 2028 | 34 |
| NCT04331288Alcoholism · United States | 1 | Completed | Pop Test Oncology | Oct 27, 2023 | 10 |
| NCT03548714Alcoholism · United States | 1 | Completed | Pop Test Oncology | Jul 15, 2019 | 10 |
| NCT00844922Depressive Disorder | 2 | Completed | Merck | Jun 2006 | 16 |
How it is read
Names in the registry
- “PT150”, 3 entries
- “SCH 900636”, 1 entry
Conditions, from the studies’ own filings
- Alcoholism, 3 studies
- Depressive Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.